Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Drugs Laggard

Tickers in this article: KERX

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model .

Keryx Biopharmaceuticals ( KERX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Keryx Biopharmaceuticals fell 7 cents (-1.1%) to $6.53 on light volume. Throughout the day, 2.5 million shares of Keryx Biopharmaceuticals exchanged hands as compared to its average daily volume of 7.4 million shares. The stock ranged in price between $6.47-$6.75 after having opened the day at $6.59 as compared to the previous trading day's close of $6.60. Other companies within the Drugs industry that declined today were: ProPhase Labs ( PRPH), down 20%, Novogen ( NVGN), down 11.4%, Prima Biomed ( PBMD), down 9.2%, and Repros Therapeutics ( RPRX), down 5.9%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. Keryx Biopharmaceuticals has a market cap of $476.1 million and is part of the health care sector. Shares are up 152.7% year to date as of the close of trading on Tuesday. Currently there are six analysts that rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.

On the positive front, Zogenix ( ZGNX), up 40.5%, Optimer Pharmaceuticals ( OPTR), up 13.2%, Oncothyreon ( ONTY), up 9.7%, and Sarepta Therapeutics ( SRPT), up 8.5%, were all gainers within the drugs industry with Pfizer ( PFE) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).